Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): AIDS

Title: AIDS (London, England)

ISSN (Electronic): 1473-5571

ISSN (Print): 0269-9370

Publication date (Electronic): Nov 28 2014

Volume: 28

Issue: 18

Affiliations

[1 ] aDepartment of Global Health bDepartment of Medicine cDepartment of Epidemiology dPediatrics & Laboratory Medicine eDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA fCenter for Clinical Research, Kenya Medical Research Institute, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret hDepartment of Obstetrics & Gynecology, University of Nairobi and Kenyatta National Hospital iCenter for Microbiology, Kenya Medical Research Institute, Nairobi, Kenya jVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA kDepartments of Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Canada. *The Partners PrEP Study Team is listed in the Acknowledgements.

Article

Publisher Item ID: 00002030-201411280-00015 Mid ID: NIHMS635151

DOI: 10.1097/QAD.0000000000000493

PMC ID: 4266161

PubMed ID: 25493602

SO-VID: 47799fd3-76b4-48fe-9231-074e733ae0e1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 24

See all cited by